Immune-Mediated Hemolytic Anemia in Dogs: Emergency Management

IMHA is a life-threatening autoimmune destruction of red blood cells in dogs, requiring intensive care and immunosuppression with careful welfare monitoring throughout treatment.

Key Facts

IMHA causes the immune system to attack and destroy its own red blood cells
Packed cell volume can drop below 10% in severe cases causing life-threatening anemia
Spherocytes on blood smear and positive Coombs' test confirm immune-mediated disease
Blood transfusions provide emergency support while immunosuppression takes effect
Prednisolone is first-line treatment, often combined with azathioprine or cyclosporine
Thromboembolic complications cause significant morbidity and mortality in IMHA
Recovery takes weeks to months; relapses occur in approximately 20-50% of cases

Welfare Considerations

IMHA is one of the most distressing acute conditions dogs can experience - profound anemia causes extreme weakness, breathlessness, collapse, and in severe cases, death before treatment can take effect. Even with optimal treatment, hospitalization involves frequent blood sampling, IV catheter maintenance, and potential transfusion reactions. Dogs recovering from IMHA require monitoring for relapse and long-term immunosuppressive medication side effects. Quality of life assessment throughout treatment is essential to guide decisions about continuing intensive management.

What You Can Do

Recognize emergency signs: sudden weakness, pale gums, collapse, rapid breathing
Seek emergency veterinary care immediately - IMHA can be fatal within hours
Discuss prognosis openly with your vet before committing to intensive treatment
Administer immunosuppressive medications precisely as prescribed - dose changes require veterinary guidance
Monitor for thromboembolic signs: sudden lameness, respiratory distress, collapse
Recheck blood counts at scheduled intervals to track response to treatment
Discuss relapse risk and long-term management with your specialist or internist